EyePoint Pharmaceuticals (EYPT) Competitors $7.13 +0.31 (+4.55%) Closing price 04:00 PM EasternExtended Trading$7.10 -0.03 (-0.42%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EYPT vs. TXG, TRNS, CTKB, LAB, SENS, ALNT, AEHR, QSI, QTRX, and MASSShould you be buying EyePoint Pharmaceuticals stock or one of its competitors? The main competitors of EyePoint Pharmaceuticals include 10x Genomics (TXG), Transcat (TRNS), Cytek Biosciences (CTKB), Standard BioTools (LAB), Senseonics (SENS), Allient (ALNT), Aehr Test Systems (AEHR), Quantum-Si (QSI), Quanterix (QTRX), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. EyePoint Pharmaceuticals vs. 10x Genomics Transcat Cytek Biosciences Standard BioTools Senseonics Allient Aehr Test Systems Quantum-Si Quanterix 908 Devices EyePoint Pharmaceuticals (NASDAQ:EYPT) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation, dividends and community ranking. Is EYPT or TXG more profitable? 10x Genomics has a net margin of -29.90% compared to EyePoint Pharmaceuticals' net margin of -226.57%. 10x Genomics' return on equity of -25.40% beat EyePoint Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets EyePoint Pharmaceuticals-226.57% -43.01% -31.63% 10x Genomics -29.90%-25.40%-19.69% Does the MarketBeat Community favor EYPT or TXG? EyePoint Pharmaceuticals received 406 more outperform votes than 10x Genomics when rated by MarketBeat users. Likewise, 70.27% of users gave EyePoint Pharmaceuticals an outperform vote while only 50.82% of users gave 10x Genomics an outperform vote. CompanyUnderperformOutperformEyePoint PharmaceuticalsOutperform Votes46870.27% Underperform Votes19829.73% 10x GenomicsOutperform Votes6250.82% Underperform Votes6049.18% Which has higher earnings & valuation, EYPT or TXG? EyePoint Pharmaceuticals has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than EyePoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEyePoint Pharmaceuticals$43.27M11.14-$70.79M-$2.31-3.0410x Genomics$610.79M1.63-$182.63M-$1.52-5.36 Does the media favor EYPT or TXG? In the previous week, 10x Genomics had 1 more articles in the media than EyePoint Pharmaceuticals. MarketBeat recorded 10 mentions for 10x Genomics and 9 mentions for EyePoint Pharmaceuticals. EyePoint Pharmaceuticals' average media sentiment score of 1.48 beat 10x Genomics' score of 1.15 indicating that EyePoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment EyePoint Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate EYPT or TXG? EyePoint Pharmaceuticals presently has a consensus price target of $26.63, suggesting a potential upside of 279.60%. 10x Genomics has a consensus price target of $18.85, suggesting a potential upside of 131.50%. Given EyePoint Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe EyePoint Pharmaceuticals is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score EyePoint Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.0010x Genomics 1 Sell rating(s) 8 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.38 Do insiders and institutionals hold more shares of EYPT or TXG? 99.4% of EyePoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 4.7% of EyePoint Pharmaceuticals shares are owned by insiders. Comparatively, 10.0% of 10x Genomics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, EYPT or TXG? EyePoint Pharmaceuticals has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500. SummaryEyePoint Pharmaceuticals beats 10x Genomics on 10 of the 18 factors compared between the two stocks. Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EYPT vs. The Competition Export to ExcelMetricEyePoint PharmaceuticalsAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$482.13M$4.13B$5.49B$7.94BDividend YieldN/A0.57%5.11%4.23%P/E Ratio-3.5127.0522.5818.55Price / Sales11.144.27397.25103.00Price / CashN/A36.1538.1834.62Price / Book1.241.666.704.26Net Income-$70.79M-$83.57M$3.23B$248.39M7 Day Performance7.25%-3.63%1.26%1.27%1 Month Performance38.89%-0.03%3.75%3.85%1 Year Performance-61.12%-33.53%15.78%5.23% EyePoint Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EYPTEyePoint Pharmaceuticals1.6931 of 5 stars$7.13+4.5%$26.63+273.4%-61.3%$469.29M$43.27M-3.57120Upcoming EarningsNews CoveragePositive NewsTXG10x Genomics4.6631 of 5 stars$7.68+2.3%$19.79+157.6%-71.8%$939.28M$610.79M-5.051,240Upcoming EarningsNews CoveragePositive NewsHigh Trading VolumeTRNSTranscat2.2477 of 5 stars$83.55-1.2%$111.50+33.5%-26.1%$777.77M$272.20M45.16920Positive NewsCTKBCytek Biosciences2.398 of 5 stars$3.70+1.4%$6.42+73.4%-38.3%$473.96M$200.45M-46.24500Upcoming EarningsPositive NewsLABStandard BioTools2.8719 of 5 stars$1.19+2.6%$2.50+110.1%-55.2%$450.99M$174.43M-1.68620Upcoming EarningsNews CoverageSENSSenseonics1.73 of 5 stars$0.60+0.0%$2.00+233.3%+52.9%$392.53M$22.47M-4.6290News CoverageALNTAllient3.9803 of 5 stars$20.32-3.3%$31.00+52.6%-27.4%$344.38M$529.97M23.091,950Upcoming EarningsShort Interest ↑AEHRAehr Test Systems3.626 of 5 stars$7.96-1.6%$25.00+214.1%-28.8%$236.98M$61.48M10.6190Positive NewsQSIQuantum-Si2.4142 of 5 stars$1.09-5.2%$3.48+218.8%-29.2%$199.62M$3.06M-1.70150News CoverageQTRXQuanterix2.2088 of 5 stars$4.89-5.0%$18.25+273.2%-64.3%$189.68M$135.44M-4.61460Upcoming EarningsAnalyst DowngradeNews CoverageMASS908 Devices1.1237 of 5 stars$4.80+0.8%$5.33+11.1%-4.7%$169.58M$59.63M-2.7160News Coverage Related Companies and Tools Related Companies TXG Alternatives TRNS Alternatives CTKB Alternatives LAB Alternatives SENS Alternatives ALNT Alternatives AEHR Alternatives QSI Alternatives QTRX Alternatives MASS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EYPT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EyePoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EYPT Stock Free EYPT Stock Alerts